The Experts below are selected from a list of 13206 Experts worldwide ranked by ideXlab platform
Martina Brueckmann - One of the best experts on this subject based on the ideXlab platform.
-
major bleeding in patients with embolic stroke of undetermined source treated with dabigatran versus Acetylsalicylic Acid re spect esus trial
Journal of the American College of Cardiology, 2019Co-Authors: Christopher B Granger, Hanschristoph Diener, Ralph Sacco, J Easton, Lisa Cronin, Mandy Frasdorf, Claudia Grauer, Martina BrueckmannAbstract:RE-SPECT ESUS™ offers an opportunity to evaluate factors associated with bleeding risk in patients with embolic stroke of unknown source (ESUS) treated with dabigatran vs Acetylsalicylic Acid (ASA). RE-SPECT ESUS was a randomized, controlled trial (570 centers in 42 countries). Patients with ESUS
-
design of randomized double blind evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate vs Acetylsalicylic Acid in patients with embolic stroke of undetermined source re spect
International Journal of Stroke, 2015Co-Authors: Hanschristoph Diener, Christopher B Granger, Lisa Cronin, Martina Brueckmann, Donald J Easton, Christine Duffy, Daniel Cotton, Ralph L SaccoAbstract:RationaleCryptogenic ischemic strokes constitute 20–30% of ischemic strokes, the majority of which are embolic strokes of undetermined source. The standard preventive treatment in these patients is usually Acetylsalicylic Acid.AimThe Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. Acetylsalicylic Acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS) is designed to determine whether the oral thrombin inhibitor dabigatran, taken within three-months after embolic stroke of undetermined source, is superior to Acetylsalicylic Acid for prevention of recurrent stroke and to characterize the safety of dabigatran in this setting.DesignProspective, randomized, double-blind, multicenter trial in approximately 6000 patients and 550 centers with embolic stroke of undetermined source. Subjects are randomized to dabigatran or Acetylsalicylic Acid and treated for an expected minimum of six-m...
-
design of randomized double blind evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate vs Acetylsalicylic Acid in patients with embolic stroke of undetermined source re spect
International Journal of Stroke, 2015Co-Authors: Hanschristoph Diener, Christopher B Granger, Lisa Cronin, Martina Brueckmann, Donald J Easton, Christine Duffy, Daniel Cotton, Ralph L SaccoAbstract:RationaleCryptogenic ischemic strokes constitute 20–30% of ischemic strokes, the majority of which are embolic strokes of undetermined source. The standard preventive treatment in these patients is usually Acetylsalicylic Acid.AimThe Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. Acetylsalicylic Acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS) is designed to determine whether the oral thrombin inhibitor dabigatran, taken within three-months after embolic stroke of undetermined source, is superior to Acetylsalicylic Acid for prevention of recurrent stroke and to characterize the safety of dabigatran in this setting.DesignProspective, randomized, double-blind, multicenter trial in approximately 6000 patients and 550 centers with embolic stroke of undetermined source. Subjects are randomized to dabigatran or Acetylsalicylic Acid and treated for an expected minimum of six-m...
Christopher B Granger - One of the best experts on this subject based on the ideXlab platform.
-
major bleeding in patients with embolic stroke of undetermined source treated with dabigatran versus Acetylsalicylic Acid re spect esus trial
Journal of the American College of Cardiology, 2019Co-Authors: Christopher B Granger, Hanschristoph Diener, Ralph Sacco, J Easton, Lisa Cronin, Mandy Frasdorf, Claudia Grauer, Martina BrueckmannAbstract:RE-SPECT ESUS™ offers an opportunity to evaluate factors associated with bleeding risk in patients with embolic stroke of unknown source (ESUS) treated with dabigatran vs Acetylsalicylic Acid (ASA). RE-SPECT ESUS was a randomized, controlled trial (570 centers in 42 countries). Patients with ESUS
-
design of randomized double blind evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate vs Acetylsalicylic Acid in patients with embolic stroke of undetermined source re spect
International Journal of Stroke, 2015Co-Authors: Hanschristoph Diener, Christopher B Granger, Lisa Cronin, Martina Brueckmann, Donald J Easton, Christine Duffy, Daniel Cotton, Ralph L SaccoAbstract:RationaleCryptogenic ischemic strokes constitute 20–30% of ischemic strokes, the majority of which are embolic strokes of undetermined source. The standard preventive treatment in these patients is usually Acetylsalicylic Acid.AimThe Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. Acetylsalicylic Acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS) is designed to determine whether the oral thrombin inhibitor dabigatran, taken within three-months after embolic stroke of undetermined source, is superior to Acetylsalicylic Acid for prevention of recurrent stroke and to characterize the safety of dabigatran in this setting.DesignProspective, randomized, double-blind, multicenter trial in approximately 6000 patients and 550 centers with embolic stroke of undetermined source. Subjects are randomized to dabigatran or Acetylsalicylic Acid and treated for an expected minimum of six-m...
-
design of randomized double blind evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate vs Acetylsalicylic Acid in patients with embolic stroke of undetermined source re spect
International Journal of Stroke, 2015Co-Authors: Hanschristoph Diener, Christopher B Granger, Lisa Cronin, Martina Brueckmann, Donald J Easton, Christine Duffy, Daniel Cotton, Ralph L SaccoAbstract:RationaleCryptogenic ischemic strokes constitute 20–30% of ischemic strokes, the majority of which are embolic strokes of undetermined source. The standard preventive treatment in these patients is usually Acetylsalicylic Acid.AimThe Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. Acetylsalicylic Acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS) is designed to determine whether the oral thrombin inhibitor dabigatran, taken within three-months after embolic stroke of undetermined source, is superior to Acetylsalicylic Acid for prevention of recurrent stroke and to characterize the safety of dabigatran in this setting.DesignProspective, randomized, double-blind, multicenter trial in approximately 6000 patients and 550 centers with embolic stroke of undetermined source. Subjects are randomized to dabigatran or Acetylsalicylic Acid and treated for an expected minimum of six-m...
Hanschristoph Diener - One of the best experts on this subject based on the ideXlab platform.
-
major bleeding in patients with embolic stroke of undetermined source treated with dabigatran versus Acetylsalicylic Acid re spect esus trial
Journal of the American College of Cardiology, 2019Co-Authors: Christopher B Granger, Hanschristoph Diener, Ralph Sacco, J Easton, Lisa Cronin, Mandy Frasdorf, Claudia Grauer, Martina BrueckmannAbstract:RE-SPECT ESUS™ offers an opportunity to evaluate factors associated with bleeding risk in patients with embolic stroke of unknown source (ESUS) treated with dabigatran vs Acetylsalicylic Acid (ASA). RE-SPECT ESUS was a randomized, controlled trial (570 centers in 42 countries). Patients with ESUS
-
design of randomized double blind evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate vs Acetylsalicylic Acid in patients with embolic stroke of undetermined source re spect
International Journal of Stroke, 2015Co-Authors: Hanschristoph Diener, Christopher B Granger, Lisa Cronin, Martina Brueckmann, Donald J Easton, Christine Duffy, Daniel Cotton, Ralph L SaccoAbstract:RationaleCryptogenic ischemic strokes constitute 20–30% of ischemic strokes, the majority of which are embolic strokes of undetermined source. The standard preventive treatment in these patients is usually Acetylsalicylic Acid.AimThe Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. Acetylsalicylic Acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS) is designed to determine whether the oral thrombin inhibitor dabigatran, taken within three-months after embolic stroke of undetermined source, is superior to Acetylsalicylic Acid for prevention of recurrent stroke and to characterize the safety of dabigatran in this setting.DesignProspective, randomized, double-blind, multicenter trial in approximately 6000 patients and 550 centers with embolic stroke of undetermined source. Subjects are randomized to dabigatran or Acetylsalicylic Acid and treated for an expected minimum of six-m...
-
design of randomized double blind evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate vs Acetylsalicylic Acid in patients with embolic stroke of undetermined source re spect
International Journal of Stroke, 2015Co-Authors: Hanschristoph Diener, Christopher B Granger, Lisa Cronin, Martina Brueckmann, Donald J Easton, Christine Duffy, Daniel Cotton, Ralph L SaccoAbstract:RationaleCryptogenic ischemic strokes constitute 20–30% of ischemic strokes, the majority of which are embolic strokes of undetermined source. The standard preventive treatment in these patients is usually Acetylsalicylic Acid.AimThe Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. Acetylsalicylic Acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS) is designed to determine whether the oral thrombin inhibitor dabigatran, taken within three-months after embolic stroke of undetermined source, is superior to Acetylsalicylic Acid for prevention of recurrent stroke and to characterize the safety of dabigatran in this setting.DesignProspective, randomized, double-blind, multicenter trial in approximately 6000 patients and 550 centers with embolic stroke of undetermined source. Subjects are randomized to dabigatran or Acetylsalicylic Acid and treated for an expected minimum of six-m...
Lisa Cronin - One of the best experts on this subject based on the ideXlab platform.
-
major bleeding in patients with embolic stroke of undetermined source treated with dabigatran versus Acetylsalicylic Acid re spect esus trial
Journal of the American College of Cardiology, 2019Co-Authors: Christopher B Granger, Hanschristoph Diener, Ralph Sacco, J Easton, Lisa Cronin, Mandy Frasdorf, Claudia Grauer, Martina BrueckmannAbstract:RE-SPECT ESUS™ offers an opportunity to evaluate factors associated with bleeding risk in patients with embolic stroke of unknown source (ESUS) treated with dabigatran vs Acetylsalicylic Acid (ASA). RE-SPECT ESUS was a randomized, controlled trial (570 centers in 42 countries). Patients with ESUS
-
design of randomized double blind evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate vs Acetylsalicylic Acid in patients with embolic stroke of undetermined source re spect
International Journal of Stroke, 2015Co-Authors: Hanschristoph Diener, Christopher B Granger, Lisa Cronin, Martina Brueckmann, Donald J Easton, Christine Duffy, Daniel Cotton, Ralph L SaccoAbstract:RationaleCryptogenic ischemic strokes constitute 20–30% of ischemic strokes, the majority of which are embolic strokes of undetermined source. The standard preventive treatment in these patients is usually Acetylsalicylic Acid.AimThe Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. Acetylsalicylic Acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS) is designed to determine whether the oral thrombin inhibitor dabigatran, taken within three-months after embolic stroke of undetermined source, is superior to Acetylsalicylic Acid for prevention of recurrent stroke and to characterize the safety of dabigatran in this setting.DesignProspective, randomized, double-blind, multicenter trial in approximately 6000 patients and 550 centers with embolic stroke of undetermined source. Subjects are randomized to dabigatran or Acetylsalicylic Acid and treated for an expected minimum of six-m...
-
design of randomized double blind evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate vs Acetylsalicylic Acid in patients with embolic stroke of undetermined source re spect
International Journal of Stroke, 2015Co-Authors: Hanschristoph Diener, Christopher B Granger, Lisa Cronin, Martina Brueckmann, Donald J Easton, Christine Duffy, Daniel Cotton, Ralph L SaccoAbstract:RationaleCryptogenic ischemic strokes constitute 20–30% of ischemic strokes, the majority of which are embolic strokes of undetermined source. The standard preventive treatment in these patients is usually Acetylsalicylic Acid.AimThe Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. Acetylsalicylic Acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS) is designed to determine whether the oral thrombin inhibitor dabigatran, taken within three-months after embolic stroke of undetermined source, is superior to Acetylsalicylic Acid for prevention of recurrent stroke and to characterize the safety of dabigatran in this setting.DesignProspective, randomized, double-blind, multicenter trial in approximately 6000 patients and 550 centers with embolic stroke of undetermined source. Subjects are randomized to dabigatran or Acetylsalicylic Acid and treated for an expected minimum of six-m...
Gilberto De Nucci - One of the best experts on this subject based on the ideXlab platform.
-
Acetylsalicylic Acid daily vs Acetylsalicylic Acid every 3 days in healthy volunteers effect on platelet aggregation gastric mucosa and prostaglandin e2 synthesis
The Journal of Clinical Pharmacology, 2016Co-Authors: Plinio Minghin Freitas Ferreira, Thiago Gaglianojuca, Tiago Zaminelli, Marinalva Ferreira Sampaio, Rory W Blackler, Miriam Trevisan, Antonio Frederico Novaes De Magalhaes, Gilberto De NucciAbstract:Substantial platelet inhibition was observed 3 days after a single administration of Acetylsalicylic Acid 81 mg to healthy volunteers. Here we investigate prostaglandin E2 (PGE2 ) antrum concentrations and gastrointestinal symptoms in two treatment groups: one receiving losartan and Acetylsalicylic Acid every day and the other receiving losartan every day and Acetylsalicylic Acid every 3 days. Twenty-eight healthy volunteers from both sexes received either 50 mg losartan and Acetylsalicylic Acid 81 mg daily or 50 mg losartan and Acetylsalicylic Acid 81 every 3 days with placebo on the other days. Therapy was delivered for 30 days for both groups. Gastric endoscopy was performed before and after treatment period. Biopsies were collected for PGE2 quantification. Platelet function tests were carried out before and during treatment and TXB2 release on platelet rich plasma was measured. The every 3 day low-dose Acetylsalicylic Acid regimen produced complete inhibition of platelet aggregation compared to the daily treatment. Thromboxane B2 release was substantially abolished for both groups during treatment. There was no significant difference on the endoscopic score of both treatment groups after the 30-day treatment (P = .215). There was over 50% suppression of antrum PGE2 content on volunteers receiving Acetylsalicylic Acid daily (P = .0016), while for the every 3 day dose regimen there was no significant difference between pre and post-treatment antrum PGE2 dosages (P = .4193). Since PGE2 is involved in gastric healing, we understand that this new approach could be safer and as efficient as the standard daily therapy on a long-term basis.
